Agios Pharmaceuticals, Inc.
$33.51
$0.70 (+2.13%)
$32.74Day Range$33.75
Key Statistics
Market Cap
$1.96B
Shares Outstanding
59.7M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Jul 24, 2013
Round Lot
100
Locale
US
Trading Data
Day Open
$32.89
Day High
$33.75
Day Low
$32.74
Volume
379.9K
VWAP
$33.46
Prev Close
$32.81
Transactions
--
Acc. Volume
--
About Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
PHARMACEUTICAL PREPARATIONSSIC 2834540 employees88 SIDNEY STREET, CAMBRIDGE, MA, 02139617-649-8600IPO Jul 24, 2013US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001439222
- Composite FIGI
- BBG000QY4ZD0
- Share Class FIGI
- BBG001T8R687
- Ticker Root
- AGIO
- SIC Code
- 2834
About Agios Pharmaceuticals, Inc. (AGIO) Stock
Agios Pharmaceuticals, Inc. (AGIO) closed the 2026-09-16 session at $33.51, up 2.13% versus the previous close (+0.70). The stock opened at $32.89 and traded between $32.74 and $33.75 during that session. Session trading volume was 380K shares. The volume-weighted average price (VWAP) is $33.46.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
Agios Pharmaceuticals, Inc. has a market capitalization of $1.96 billion. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. AGIO is listed on the XNAS exchange. The company employs approximately 540 people. Agios Pharmaceuticals, Inc. is headquartered in CAMBRIDGE, MA. The recorded listing date is 2013-07-24.
On this page you can find market AGIO stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.